Can we improve on XALKORI? New agents for patients with an ALK-1 rearrangement

Dr. Mary Pinder reviews with Nathan Pennell and Howard West promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets. Video by

oncoJC: Urogenital Cancer

On April 10th, 2013, our first “all-online” Journal Club was moderated by Dr. med. Richard Cathomas and joined by PD Dr. med. Frank Stenner and Dr. med. Philippe von Burg. The paper discussed was 2-weekly vs. 3-weekly docetaxel to treat castration-resistant prostate cancer: a randomised phase 3 trial by Kellokumpu-Lehtinen et al.; Lancet Oncology 2013;14:117-124 (abstract).

After a short introduction to the paper by Richard Cathomas, the participant discussed the value and the limitations of the finding that a 2-weekly administration of docetaxel leads to comparable results to a 3-weekly scheme, if a change of therapy will be implemented in their clinical work and if so, for which patients.

Please post questions or comments above (leave a reply)  and we will refer them to the discussants.

Interview with Prof. Kluin-Nelemans

As the first entry to this Journal Club, we are pleased to present you an interview with Prof. HC Kluin-Nelemans from the University of Groningen, moderated by PD Dr. Christoph Renner and supported by PD Dr. Frank Stenner, about her recent paper Treatment of Older Patients with Mantle-Cell Lymphoma (free access) in the New England Journal of Medicine. We would like to thank everybody for being available at the 4th SSHO Meeting in Basel and especially Prof Kluin-Nelemans for answering questions so shortly before her talk.